27-06-2022 Relapsed Refractory Hodgkin Lymphoma management

In this Deep Dive Session, Prof. Pier Luigi Zinzani, from the University of Bologna, discusses the use of PD-1 inhibitors in the treatment of relapsed or refractory Hodgkin’s lymphoma. He presents data from various studies, including his own, highlighting the effectiveness of these inhibitors and the potential for their use in combination with other treatments, such as allogeneic stem cell transplantation.

See more from BLOODSA

Scroll to Top